

## Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference

November 13, 2009

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 13, 2009-- Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company's executive vice president and chief financial officer, will present at Lazard's 6 <sup>th</sup> Annual Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York. Mr. Karbe will discuss the company's corporate strategy, financial outlook and development pipeline.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

## About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at <a href="http://www.exelixis.com">www.exelixis.com</a>.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc. Investor Contacts: Charles Butler, 650-837-7277 Vice President, Investor Relations and Corporate Communications <u>cbutler @ exelixis.com</u> or DeDe Sheel, 650-837-8231 Associate Director, Investor Relations <u>dsheel @ exelixis.com</u>